Agenda
Times are displayed in the event's local time (GMT -05:00)
10:00 - 12:05
MAIN PLENARY: Welcome & Presidential Symposium
10:00 - 10:15 AM (EST) Welcome to ASENT Annual Meeting 2021
Thomas Sutula, MD, PhD, ASENT President | Professor Emeritus, University of Wisconsin-Madison
10:15 - 11:50 AM (EST) PRESIDENTIAL SYMPOSIUM: COVID-19 and the Nervous System as a Basic Medical and Therapeutic Challenge
CHAIRS:
Thomas Sutula, MD, PhD, ASENT President | Professor Emeritus, University of Wisconsin-Madison
C. Anthony Altar, PhD, President and Chief Operating Officer, Splice Therapeutics
Carole Burns, PhD, Director, Translational and Asset Development, GEn1E Lifesciences Inc
Symposium to cover 1918 flu pandemic, the COVID-19 pandemic and neurological consequences. Stroke, olfactory (anosmia) and gustatory deficits and other neurological complications result from COVID-19 infection. The delayed appearance of postencephalitic Parkinsonism in people surviving the 1918 flu and those contracting encephalitis lethargica around the same time indicate hidden, protracted risks may await those who survive viral pandemics. These topics and an update of neurological complications of COVID-19 will be reviewed in this symposium.
10:15 - 10:45 AM (EST) KEYNOTE PRESENTATION: Neurological Consequences of Viral Pandemics including COVID-19
Avindra (Avi) Nath, MD, Chief of the Section of Infections of the Nervous System, National Institute of Neurological Disorders and Stroke
10:45 - 10:55 AM (EST) Live Q&A with KEYNOTE SPEAKER
Avindra (Avi) Nath, MD, Chief of the Section of Infections of the Nervous System, National Institute of Neurological Disorders and Stroke
10:55 - 11:15 AM (EST) Neurological Impact During Acute COVID-19: Marked CNS Immune Activation but No Clear Evidence of Viral Invasion
Arvid Edén, MD, PhD, Senior Consultant, Department of Infectious Diseases, Sahlgrenska University Hospital
11:15 - 11:35 AM (EST) The Long Goodbye: Understanding Neurologic Symptoms Post-Acute COVID-19
Serena Spudich, MD, Chief, Neuroinfectious Diseases and Global Neurology, Yale University
11:35 - 11:50 AM (EST) Live Faculty Panel Discussion and Q&A
Arvid Edén, MD, PhD, Senior Consultant, Department of Infectious Diseases, Sahlgrenska University Hospital
Avindra (Avi) Nath, MD, Chief of the Section of Infections of the Nervous System, National Institute of Neurological Disorders and Stroke
Serena Spudich, MD, Chief, Neuroinfectious Diseases and Global Neurology, Yale University
11:50 AM - 12:05 PM (EST) BREAK
12:05 - 13:40
BREAKOUT SESSIONS (HALL A or B)
HALL A - Obstacles and Opportunities in Alzheimer's Disease Neurotherapeutics
CHAIRS:
Bennett Lavenstein, MD, Director, Movement Disorders Program, Children's National Hospital
Sharon Tamir, Head of GBM and Rare Oncology Indications, Karyopharm Therapeutics
Speakers will address barriers to success, the use of natural history and investigation of drug repurposing in the search for solutions in Alzheimer's Disease neurotherapeutics.
HALL B - RNA Editing and CRISPR Technology: Basic Approaches and Treatment Implications for Neurologic Disease
CHAIRS:
Ann-Marie Broome, MBA, PhD, Program Director, CREATE bio and URGenT Network, National Institute of Neurological Disorders and Stroke
Lloyd Mitchell, MD, CEO and Chief Scientific Officer, RetroTherapy
Discussion of gene editing as an advancement in gene therapy including DNA and RNA editing, Molecular mechanims, clinical potentials of genome editing systems, and therapeutic development in neurological disorders.
1:25 - 1:40 PM (EST) BREAK
13:40 - 14:45
MAIN PLENARY: Overview of Medical Device Regulatory Pathways in the United States & Xenon Pharmaceuticals Sponsored Symposium
1:40 - 2:05 PM (EST) Overview of Medical Device Regulatory Pathways in the United States
CAPT. Nina Mezu-Nwaba, PharmD, MPH, MSc, Deputy Director, OHT5: Office of Neurological and Physical Medicine Devices, Office of Product Evaluation and Quality, CDRH, Food and Drug Administration
2:05 - 2:15 PM (EST) Live Faculty Discussion and Q&A
CAPT. Nina Mezu-Nwaba, PharmD, MPH, MSc, Deputy Director, OHT5: Office of Neurological and Physical Medicine Devices, Office of Product Evaluation and Quality, CDRH, Food and Drug Administration
2:15 - 2:35 PM (EST) Xenon Pharmaceuticals Sponsored Symposium: Addressing an Unmet Medical Need in Adult Focal Epilepsy with XEN1101, a Novel KV7 Modulator
Dr. Ernesto Aycardi, Chief Medical Officer, Xenon Pharmaceuticals Inc.
Focal Adult Epilepsy is a common form of epilepsy with a high unmet medical need. Patients frequently require polypharmacy to control their seizures. In addition to the efficacy of a drug, the safety, tolerability and ease of use are very important for patients and caregivers since they have an impact on adherence and compliance and consequently clinical outcomes. Xenon Pharmaceuticals is developing XEN1101, a novel, only in-class KV7 opener with unique pharmaceutical properties and a favorable risk-benefit profile in Phase 1 studies and in an ongoing Phase 2b trial. This presentation will provide an overview of XEN1101 as a potentially highly differentiated molecule from currently available products for focal epilepsy where the medical need is high.
2:35 - 2:45 PM (EST) Live Faculty Discussion and Q&A
Dr. Ernesto Aycardi, Chief Medical Officer, Xenon Pharmaceuticals Inc.
14:55 - 16:20
POSTER DISCUSSION HALL & Closing Comments from ASENT President
12:05 - 13:40
BREAKOUT SESSION - Obstacles and Opportunities in Alzheimer's Disease Neurotherapeutics
CHAIRS:
Bennett Lavenstein, MD, Director, Movement Disorders Program, Children's National Hospital
Sharon Tamir, Head of GBM and Rare Oncology Indications, Karyopharm Therapeutics
Speakers will address barriers to success, the use of natural history and investigation of drug repurposing in the search for solutions in Alzheimer's Disease neurotherapeutics.
12:10 - 12:30 PM (EST) Advances in Alzheimer's Disease and Related Dementia Research
Eliezer Masliah, MD, Director of the Division of Neuroscience, National Institute on Aging (NIA), NIH
12:30 - 12:50 PM (EST) Leveraging Dominantly Inherited Alzheimer Disease for Current and Future Alzheimer Therapeutics
Eric McDade, DO, Associate Professor of Neurology, Washington University School of Medicine in St. Louis
12:50 - 1:10 PM (EST) Barriers to Success/Opportunities in Alzheimer's on the Basis of Prior or Forthcoming Trials
Dennis Selkoe, MD, Professor of Neurologic Diseases, Harvard Medical School and Brigham and Women’s Hospital
1:10 - 1:25 PM (EST) Live Faculty Panel Discussion and Q&A
Eliezer Masliah, MD, Director of the Division of Neuroscience, National Institute on Aging (NIA), NIH
Eric McDade, DO, Associate Professor of Neurology, Washington University School of Medicine in St. Louis
Dennis Selkoe, MD, Professor of Neurologic Diseases, Harvard Medical School and Brigham and Women’s Hospital
1:25 - 1:40 PM (EST) BREAK
12:05 - 13:40
BREAKOUT SESSION - RNA Editing and CRISPR Technology: Basic Approaches and Treatment Implications for Neurologic Disease
CHAIRS:
Ann-Marie Broome, MBA, PhD, Program Director, CREATE bio and URGenT Network, National Institute of Neurological Disorders and Stroke
Lloyd Mitchell, MD, CEO and Chief Scientific Officer, RetroTherapy
Discussion of gene editing as an advancement in gene therapy including DNA and RNA editing, Molecular mechanims, clinical potentials of genome editing systems, and therapeutic development in neurological disorders.
12:10 - 12:30 PM (EST) Base Editing and Prime Editing: Genome Editing Without Double-Strand Breaks
David Liu, PhD, Merkin Institute of Transformative Technologies in Healthcare, Broad Institute; Harvard University; Howard Hughes Medical Institute
12:30 - 12:50 PM (EST) RNA Editing by Trans-Splicing for Neurological Diseases
Lloyd Mitchell, MD, CEO and Chief Scientific Officer, RetroTherapy
12:50 - 1:10 PM (EST) Gene Therapy & Gene Editing Approaches for Retinal Diseases
Abraham Scaria, PhD, Chief Scientific Officer, IVERIC bio, Inc.
1:10 - 1:25 PM (EST) Live Faculty Panel Discussion and Q&A
David Liu, PhD, Merkin Institute of Transformative Technologies in Healthcare, Broad Institute; Harvard University; Howard Hughes Medical Institute
Lloyd Mitchell, MD, CEO and Chief Scientific Officer, RetroTherapy
Abraham Scaria, PhD, Chief Scientific Officer, IVERIC bio, Inc.
1:25 - 1:40 PM (EST) BREAK
14:45 - 15:40
POSTER DISCUSSION & Closing Comments
2:55 - 4:00 PM (EST) POSTER DISCUSSION
MODERATOR:
Carolyn Tallon, PhD, Johns Hopkins University School of Medicine
The following posters presenters will be available for a live Q&A:
1. Examining Regeneration Capacity and Innervation of NMJs by iPSC-Derived Motor Neurons
Ms. Katherine Marshall, Johns Hopkins University School of Medicine
2. Clinical and genetic complexity among patients with the progressive mitochondrial neurodegenerative disease LHON-Plus
Dr. Anne Chiaramello, George Washington University School of Medicine and Health Sciences
3. Pharmacokinetics, Food Effect, and Relative Bioavailability of Two Formulations of NBI-921352/XEN901 (Novel NaV1.6-Selective Sodium Channel Blocker) in Healthy Adults: Pediatric Granules and Adult Tablets
Dr. Gregory Beatch, Xenon Pharmaceuticals
4. Potential Drug-Drug Interactions Between NBI-921352/XEN901 (a Novel Nav1.6 Selective Sodium Channel Blocker) and a Strong Inducer of CYP3A4 (Phenytoin) in Healthy Volunteers
Dr. Gordon Loewen, Xenon Pharmaceuticals
5. Utilizing Human Subjects Research Protection Trainings and Site Initiation Visits to Improve Participant Safety in Clinical Neurology Research
Dr. Matthew Gooden, National Institute of Neurological Disorders and Stroke, National Institutes of Health
6. Safety and Pharmacokinetics of Antisense Oligonucleotide STK-001 in Children and Adolescents with Dravet Syndrome: Design of the Open-Label Phase 1/2a MONARCH Study
Dr. Javier Avendaño, Stoke Therapeutics
7. NIH HEAL Initiative: NINDS Preclinical Screening Platform for Pain (PSPP)
Dr. Sarah Woller, National Institute of Neurological Disorders and Stroke, National Institutes of Health
9. Establishment of a reversal learning assay in rats to investigate the effects of novel compounds on executive function
Dr. Fionn Dunphy-Doherty, Transpharmation Ireland Ltd.
4:00 - 4:05 PM (EST) Closing Comments from ASENT President
Thomas Sutula, MD, PhD, ASENT President | Professor Emeritus, University of Wisconsin-Madison
10:00 - 11:45
BREAKOUT SESSIONS (HALL A or B) & Welcome
10:00 - 10:10 AM (EST) Welcome to ASENT Annual Meeting 2021
Thomas Sutula, MD, PhD, ASENT President | Professor Emeritus, University of Wisconsin-Madison
10:10 - 11:30 AM (EST) BREAKOUT SESSIONS
HALL A - Leveraging Unconventional (Big) Clinical Datasets for Treatment in Epilepsy
CHAIRS:
Aditya Joshi, MD, Department of Neurology, University of Pennsylvania
Danilo Vitorovic, MD, Neurologist and Division Chief, University of Vermont Medical Center
There is vast amount of data generated in the modern clinical practice of epilepsy, which is now more accessible than ever with the tools of Big Data. In this symposium, we will explore some of the efforts to tap this vast trove to advance the treatment of patients with epilepsy.
HALL B - Dystonia: Genetics, Pathophysiology, New Targets and Treatment
CHAIRS:
Stewart Factor, DO, Professor of Neurology, Director of the Movement Disorders Program and Vance Lanier Chair of Neurology, Emory University School of Medicine
Debra Ehrlich, MD, Chief of the Parkinson’s Disease Clinic, National Institute of Neurological Disorders and Stroke
Faculty will address genes and mechanisms in Dystonia, pathophysiology specific to dystonia as well as, new targets and treatments to address the disease state.
11:30 - 11:45 PM (EST) BREAK
11:45 - 13:20
MAIN PLENARY: PIPELINE PRESENTATIONS - Emerging Neurotherapeutics Pipeline
11:45 AM - 1:05 PM (EST) PIPELINE PRESENTATION - Emerging Neurotherapeutics Pipeline
1. The NINDS Ultra-Rare Gene-based Therapy network: An URGenT need for ultra-rare neurological diseases
Dr. Ann-Marie Broome, National Institutes of Health
2. Efficacy and Safety of AXS-05, an Oral, NMDA Receptor Antagonist with Multimodal Activity in Major Depressive Disorder: Results from the ASCEND Phase 2, Double-blind, Active-controlled Trial
Dr. Amanda Jones, Axsome Therapeutics
3. Efficacy and Safety of AXS-05, an Oral, NMDA Receptor Antagonist with Multimodal Activity in Major Depressive Disorder: Results from the GEMINI Phase 3, Double-Blind, Placebo-Controlled Trial
Dr. Cedric O'Gorman, Axsome Therapeutics
4. Functional and Long-Term Survival Data of AMX0035 in Amyotrophic Lateral Sclerosis: Results of the CENTAUR Trial
Dr. Sabrina Paganoni, Massachusetts General Hospital; Harvard University
5. GM6 attenuates inflammation in Alzheimer’s disease pathology concurrently with reducing Beta Amyloid and phosphorylated tau
Dr. Mark Kindy, University of South Florida
6. Alzheimer’s Disease Preclinical Efficacy Database (AlzPED): Optimizing the Predictive Power of Drug Efficacy Studies in Alzheimer’s Disease Animal Models
Dr. Shreaya Chakroborty, National Institutes of Health
7. Modulation of the p38 MAPK Pathway in Peripheral Blood Mononuclear Cells: Implications for Screening Novel Anti-Inflammatories in Alzheimer’s Disease
Mr. Luke Davison, Transpharmation Ireland Ltd.
12:50 - 1:05 PM (EST) Live Faculty Panel Discussion and Q&A
1:05 - 1:20 PM (EST) BREAK
13:20 - 13:55
MAIN PLENARY: SynapCell Sponsored Symposium
1:20 - 1:40 PM (EST) CUE® Phenotyping Platform, Turning Observations into Facts
Hugo Monchal, MSc, International Sales Engineer USA/LATAM, SynapCell
To be more effective, CNS Drug Discovery needs objective and quantitative tools not only to identify new promising Neurotherapeutics but also to upgrade the translational power of preclinical rodent models of CNS disorders.
Characterizing animal models with SynapCell’s CUE® Phenotyping Platform allows to align preclinical and clinical roadmaps with predictive EEG biomarkers, and to turn them into powerful drug discovery tools
1:40 - 1:50 PM (EST) Live Faculty Panel Discussion and Q&A
Hugo Monchal, MSc, International Sales Engineer USA/LATAM, SynapCell
14:00 - 15:30
POSTER DISCUSSION HALL & Closing Comments from ASENT President
10:00 - 11:45
BREAKOUT SESSION - Leveraging Unconventional (Big) Clinical Datasets for Treatment in Epilepsy
10:00 - 10:10 AM (EST) Welcome to ASENT Annual Meeting 2021
Thomas Sutula, MD, PhD, ASENT President | Professor Emeritus, University of Wisconsin-Madison
10:10 - 11:30 AM (EST) BREAKOUT SESSION - Leveraging Unconventional (Big) Clinical Datasets for Treatment in Epilepsy
CHAIRS:
Aditya Joshi, MD, Department of Neurology, University of Pennsylvania
Danilo Vitorovic, MD, Neurologist and Division Chief, University of Vermont Medical Center
There is vast amount of data generated in the modern clinical practice of epilepsy, which is now more accessible than ever with the tools of Big Data. In this symposium, we will explore some of the efforts to tap this vast trove to advance the treatment of patients with epilepsy.
10:15 - 10:35 AM (EST) Natural Language Processing of EEG Reports to Learn Seizure Onsets
Christopher Lee-Messer, MD, PhD, Clinical Assistant Professor, Neurology & Neurological Sciences and Pediatrics - Operations, Stanford University
10:35 - 10:55 AM (EST) Discovering Genotype - Phenotype Correlations Hidden in the EMR
Colin Ellis, MD, Assistant Professor of Neurology, University of Pennsylvania; Children's Hospital of Philadephia
10:55 - 11:15 AM (EST) Applying Artificial Intelligence to Epilepsy Care: from Scanner to Bedside
Ezequiel (Zeke) Gleichgerrcht, MD, PhD, Clinical Instructor, Neurology, Medical University of South Carolina
11:15 - 11:30 AM (EST) Live Faculty Panel Discussion and Q&A
Colin Ellis, MD, Assistant Professor of Neurology, University of Pennsylvania; Children's Hospital of Philadephia
Ezequiel (Zeke) Gleichgerrcht, MD, PhD, Clinical Instructor, Neurology, Medical University of South Carolina
Christopher Lee-Messer, MD, PhD, Clinical Assistant Professor, Neurology & Neurological Sciences and Pediatrics - Operations, Stanford University
11:30 - 11:45 PM (EST) BREAK
10:00 - 11:45
BREAKOUT SESSION - Dystonia: Genetics, Pathophysiology, New Targets and Treatment
10:00 - 10:10 AM (EST) Welcome to ASENT Annual Meeting 2021
Thomas Sutula, MD, PhD, ASENT President | Professor Emeritus, University of Wisconsin-Madison
10:10 - 11:30 AM (EST) BREAKOUT SESSION - Dystonia: Genetics, Pathophysiology, New Targets and Treatment
CHAIRS:
Stewart Factor, DO, Professor of Neurology, Director of the Movement Disorders Program and Vance Lanier Chair of Neurology, Emory University School of Medicine
Debra Ehrlich, MD, Chief of the Parkinson’s Disease Clinic, National Institute of Neurological Disorders and Stroke
Faculty will address genes and mechanisms in dystonia, pathophysiology specific to dystonia as well as, new targets and treatments to address the disease state.
10:15 - 10:35 AM (EST) Dystonia Genes & Mechanisms
H.A. (Buz) Jinnah, MD, Professor, Departments of Neurology and Human Genetics, Emory University School of Medicine
10:35 - 10:55 AM (EST) Pathophysiology in Dystonia
Mark Hallett, MD, Distinguished Investigator, Human Motor Control Section, National Institute of Neurological Disorders and Stroke
10:55 - 11:15 AM (EST) New Targets and Treatments in Dystonia
Susan Fox, PhD, MB BCh, Associate Professor, Division of Neurology, University of Toronto and Neurologist, Krembil Research Institute - University Health Network
11:15 - 11:30 AM (EST) Live Faculty Panel Discussion and Q&A
Susan Fox, PhD, MB BCh, Associate Professor, Division of Neurology, University of Toronto and Neurologist, Krembil Research Institute - University Health Network
Mark Hallett, MD, Distinguished Investigator, Human Motor Control Section, National Institute of Neurological Disorders and Stroke
H.A. (Buz) Jinnah, MD, Professor, Departments of Neurology and Human Genetics, Emory University School of Medicine
11:30 - 11:45 PM (EST) BREAK
13:55 - 14:55
POSTER DISCUSSION & Closing Comments
2:00 - 3:05 PM (EST) POSTER DISCUSSION
MODERATOR:
Carolyn Tallon, PhD, Johns Hopkins University School of Medicine
The following posters presenters will be available for a live Q&A:
10. The NINDS Ultra-Rare Gene-based Therapy network: An URGenT need for ultra-rare neurological diseases
Dr. Ann-Marie Broome, NIH National Institute of Neurological Disorders and Stroke
11. Efficacy and Safety of AXS-05, an Oral, NMDA Receptor Antagonist with Multimodal Activity in Major Depressive Disorder: Results from the ASCEND Phase 2, Double-blind, Active-controlled Trial
Dr. Amanda Jones, Axsome Therapeutics
12. Efficacy and Safety of AXS-05, an Oral, NMDA Receptor Antagonist with Multimodal Activity in Major Depressive Disorder: Results from the GEMINI Phase 3, Double-Blind, Placebo-Controlled Trial
Dr. Cedric O'Gorman, Axsome Therapeutics
13. Functional and Long-Term Survival Data of AMX0035 in Amyotrophic Lateral Sclerosis: Results of the CENTAUR Trial
Dr. Sabrina Paganoni, Massachusetts General Hospital, Harvard Medical School
14. GM6 attenuates inflammation in Alzheimer’s disease pathology concurrently with reducing Beta Amyloid and phosphorylated tau
Dr. Mark Kindy, University of South Florida
15. Alzheimer’s Disease Preclinical Efficacy Database (AlzPED): Optimizing the Predictive Power of Drug Efficacy Studies in Alzheimer’s Disease Animal Models
Dr. Shreaya Chakroborty, National Institute on Aging
16. Modulation of the p38 MAPK Pathway in Peripheral Blood Mononuclear Cells: Implications for Screening Novel Anti-Inflammatories in Alzheimer’s Disease
Mr. Luke Davison, Transpharmation Ireland Ltd.
17. Dimethyl fumarate suppresses neurodegeneration through reduction of M1 macrophages-induced A1 reactive astrocytes and complement C3 deposition
Dr. Sudhir Kumar Yadav, Rutgers-Robert Wood Johnson Medical School
18. Development of a Reconstituted Assay to Test Casein Kinase 1δ Inhibitors to Block Alzheimer’s Disease Progression
Dr. Sabyasachi Chatterjee, Xavier University of Louisiana
3:05 - 3:10 PM (EST) Closing Comments from ASENT President
Thomas Sutula, MD, PhD, ASENT President | Professor Emeritus, University of Wisconsin-Madison
10:00 - 11:45
BREAKOUT SESSIONS (HALL A or B) & Welcome
10:00 - 10:10 AM (EST) Welcome to ASENT Annual Meeting 2021
Thomas Sutula, MD, PhD, ASENT President | Professor Emeritus, University of Wisconsin-Madison
10:10 - 11:30 AM (EST) BREAKOUT SESSIONS
HALL A - Physiological Markers and Epigenetic Risk Factors in Neurodegenerative Disorders
CHAIRS:
Amy Chappell, MD, Chief Medical Officer, Eliem Therapeutics
Suhayl Dhib - Jalbut, MD, Professor and Chairman of the Departments of Neurology, Rutgers-Robert Wood Johnson Medical School & New Jersey Medical School
This session will cover the physiological markers of stress and aging, epigenetic regulation of myelination and demyelination, and MS susceptibility variants exert local and distal effects on the T cell epigenome.
HALL B - Emerging Therapeutics in NeuroOncology
CHAIR:
Sharon Tamir, Head of GBM and Rare Oncology Indications, Karyopharm Therapeutics
Carole Burns PhD, Director, Translational and Asset Development, GEn1E Lifesciences Inc.
Glioblastoma Multiforme (GBM) is one of the most common and particularly aggressive forms of brain tumors of primarily glial cell origin. GBM is an incurable disease with few treatment advances for many years. Speakers will discuss new potential treatments and development in the field of GBM and other neuro-oncology diseases
11:30 - 11:45 PM (EST) BREAK
11:45 - 13:20
MAIN PLENARY: PIPELINE PRESENTATIONS - Emerging Neurotherapeutics Pipeline
11:45 AM - 1:05 PM (EST) PIPELINE PRESENTATIONS - Emerging Neurotherapeutics Pipeline
1. Evaluation of novel non-opioid, non-addictive pain therapeutics within the NIH HEAL Initiative PSPP program- a case study
Dr. Smriti Iyengar, National Institute of Neurological Disorders and Stroke, National Institutes of Health
2. Anticonvulsant Effects of the Differentiated Kv7 Channel Potentiator XEN1101 in Combination with Commonly Used Anti-Seizure Drugs
Dr. J.P. Johnson, Xenon Pharmaceuticals
3. Depression and Anhedonia: Acute Preclinical Efficacy for XEN1101, a Differentiated Kv7 Potassium Channel Modulator
Dr. Alison Cutts, Xenon Pharmaceuticals
4. The neutral sphingomyelinase 2 inhibitor PDDC reduces tau burden in Alzheimer’s disease mice
Dr. Carolyn Tallon, Johns Hopkins Drug Discovery
5. Sleep disturbances in murine models of HIV-infection
Dr. Ben Bell, Johns Hopkins School of Medicine
6. Modulation of TREM2 Mechanism as a potential treatment for neurodegenerative diseases
Dr. Rafael Nir, SBH Sciences
7. Targeted Inhibition of CDK5-mediated Regulation of Human Endogenous Retrovirus K Envelope Protein in Atypical Teratoid Rhabdoid Tumor
Dr. Tara Doucet-O'Hare, National Institute of Neurological Disorders and Stroke, National Cancer Institute
12:50 - 1:05 PM (EST) Live Faculty Panel Discussion and Q&A
1:05 - 1:20 PM (EST) BREAK
13:20 - 13:55
MAIN PLENARY: Xenon Pharmaceuticals Sponsored Symposium
1:20 - 1:40 PM (EST) KV7 Modulators in Epilepsy and Depression
Dr Robin Sherrington, PhD, Executive Vice President, Strategy & Innovation, Xenon Pharmaceuticals Inc.
XEN1101 is a differentiated next generation KV7 potassium channel modulator being developed for the treatment of epilepsy and potentially other neurological disorders. Major depression is a common co-morbidity of persons with epilepsy and significantly impacts their quality of life. This presentation will provide an overview of preclinical and clinical data suggesting KV7 channel modulators may have a beneficial impact on depression and anhedonia, in addition to anti-seizure activity.
1:40 - 1:50 PM (EST) Live Faculty Discussion and Q&A
Dr Robin Sherrington, PhD, Executive Vice President, Strategy & Innovation, Xenon Pharmaceuticals Inc.
14:00 - 15:30
POSTER DISCUSSION HALL & Closing Comments from ASENT President
10:00 - 11:45
BREAKOUT SESSION - Physiological Markers and Epigenetic Risk Factors in Neurodegenerative Disorders
10:00 - 10:10 AM (EST) Welcome to ASENT Annual Meeting 2021
Thomas Sutula, MD, PhD, ASENT President | Professor Emeritus, University of Wisconsin-Madison
10:10 - 11:30 AM (EST) BREAKOUT SESSION - Physiological Markers and Epigenetic Risk Factors in Neurodegenerative Disorders
CHAIRS:
Amy Chappell, MD, Chief Medical Officer, Eliem Therapeutics
Suhayl Dhib - Jalbut, MD, Professor and Chairman of the Departments of Neurology, Rutgers-Robert Wood Johnson Medical School & New Jersey Medical School
This session will cover the physiological markers of stress and aging, epigenetic regulation of myelination and demyelination, and MS susceptibility variants exert local and distal effects on the T cell epigenome.
10:15 - 10:35 AM (EST) Multiple Sclerosis Susceptibility Variants Exert Local and Distal Effects on the T Cell Epigenome
Philip DeJager, MD, PhD, Professor of Neurology, Columbia University
10:35 - 10:55 AM (EST) Physiological Markers of Stress and Aging
David Ziegler, PhD, Director of Multimodal Biosensing, Technology Division - Neuroscape; Associate Professional Researcher - Neurology, University of California, San Francisco
10:55 - 11:15 AM (EST) Epigenetic Regulation of Myelination and Remyelination
Patrizia Casaccia, MD, PhD, Chief of the Center of Excellence for Myelin Repair, Friedman Brain Institute at Mount Sinai School of Medicine
11:15 - 11:30 AM (EST) Live Faculty Panel Discussion and Q&A
Patrizia Casaccia, MD, PhD, Chief of the Center of Excellence for Myelin Repair, Friedman Brain Institute at Mount Sinai School of Medicine
Philip DeJager, MD, PhD, Professor of Neurology, Columbia University
David Ziegler, PhD, Director of Multimodal Biosensing, Technology Division - Neuroscape; Associate Professional Researcher - Neurology, University of California, San Francisco
11:30 - 11:45 PM (EST) BREAK
10:00 - 11:45
BREAKOUT SESSION - Emerging Therapeutics in NeuroOncology
10:00 - 10:10 AM (EST) Welcome to ASENT Annual Meeting 2021
Thomas Sutula, MD, PhD, ASENT President | Professor Emeritus, University of Wisconsin-Madison
10:10 - 11:30 AM (EST) BREAKOUT SESSION - Emerging Therapeutics in NeuroOncology
CHAIR:
Sharon Tamir, Head of GBM and Rare Oncology Indications, Karyopharm Therapeutics
Carole Burns, PhD, Director, Translational and Asset Development, GEn1E Lifesciences Inc.
Glioblastoma Multiforme (GBM) is one of the most common and particularly aggressive forms of brain tumors of primarily glial cell origin. GBM is an incurable disease with few treatment advances for many years. Speakers will discuss new potential treatments and development in the field of GBM and other neuro-oncology diseases
10:15 - 10:35 AM (EST) New Horizons for TTFields in Neuro-Oncology
Moshe Giladi, PhD, MBA, Head of Preclinical Research, novocure
10:35 - 10:55 AM (EST) Selinexor, Selective Inhibitor of Nuclear Export (SINE) Compound in Neuro-Oncology
J. Paul Duic, MD, Senior Medical Director, Clinical Development, Karyopharm Therapeutics
10:55 - 11:15 AM (EST) Using the Mayo GBM PDX Collection as a Platform for Developing Novel Combination Therapies for GBM
Jann Sarkaria, MD, Professor of Radiation Oncology, Mayo Clinic
11:15 - 11:30 AM (EST) Live Faculty Panel Discussion and Q&A
J. Paul Duic, MD, Senior Medical Director, Clinical Development, Karyopharm Therapeutics
Moshe Giladi, PhD, MBA, Head of Preclinical Research, novocure
Jann Sarkaria, MD, Professor of Radiation Oncology, Mayo Clinic
11:30 - 11:45 PM (EST) BREAK
13:55 - 15:00
POSTER DISCUSSION & Closing Comments
2:00 - 3:05 PM (EST) POSTER DISCUSSION
MODERATOR:
Carolyn Tallon, PhD, Johns Hopkins University School of Medicine
The following posters presenters will be available for a live Q&A:
19. Evaluation of novel non-opioid, non-addictive pain therapeutics within the NIH HEAL Initiative PSPP program- a case study
Dr. Smriti Iyengar, National Institute of Neurological Disorders and Stroke, National Institutes of Health
20. Depression and Anhedonia: Acute Preclinical Efficacy for XEN1101, a Differentiated Kv7 Potassium Channel Modulator
Dr. Alison Cutts, Xenon Pharmaceuticals
21. Anticonvulsant Effects of the Differentiated Kv7 Channel Potentiator XEN1101 in Combination with Commonly Used Anti-Seizure Drugs
Dr. J.P. Johnson, Xenon Pharmaceuticals
22. The neutral sphingomyelinase 2 inhibitor PDDC reduces tau burden in Alzheimer’s disease mice
Dr. Carolyn Tallon, Johns Hopkins Drug Discovery
23. Sleep disturbances in murine models of HIV-infection
Dr. Ben Bell, Johns Hopkins School of Medicine
24. Modulation of TREM2 Mechanism as a potential treatment for neurodegenerative diseases
Dr. Rafael Nir, SBH Sciences
25. Targeted Inhibition of CDK5-mediated Regulation of Human Endogenous Retrovirus K Envelope Protein in Atypical Teratoid Rhabdoid Tumor
Dr. Tara Doucet-O'Hare, National Institute of Neurological Disorders and Stroke, National Cancer Institute
26. Neurophysiological Biomarkers of Dorsal and Ventral Subthalamic Nucleus in Parkinson’s Patients
Mr. Jeffrey Nie, Southern Illinois University School of Medicine
27. Impact of Neuregulin 1 Type III overexpression on motor axon development in Spinal Muscular Atrophy (SMA) model mice
Mr. Jeffrey Petigrow, Johns Hopkins University
3:05 - 3:10 PM (EST) Closing Comments from ASENT President
Thomas Sutula, MD, PhD, ASENT President | Professor Emeritus, University of Wisconsin-Madison
10:00 - 11:45
BREAKOUT SESSIONS (HALL A or B) & Welcome
10:00 - 10:10 AM (EST) Welcome to ASENT Annual Meeting 2021
Thomas Sutula, MD, PhD, ASENT President | Professor Emeritus, University of Wisconsin-Madison
10:10 - 11:30 AM (EST) BREAKOUT SESSIONS
HALL A - Brain Organoids as Models of Neurological Disorders and Treatment
CHAIRS:
C. Anthony Altar, PhD, President and Chief Operating Officer, Splice Therapeutics
Amir Tamiz, PhD, Director of the Division of Translational Research, National Institute of Neurological Disorders and Stroke
Speakers will describe the technology behind creating three-dimensional cell clusters that resemble peripheral and central nervous tissue, and how these CNS and PNS models show phenotypes consistent with CNS tissue, and diseases that plagued donors of the progenitor cells used to make these cell systems. The use of organoids to evaluate known and novel therapeutic agents, including gene therapies, will also be shown.
HALL B - Parkinson's Disease: New Approaches
CHAIRS:
Stewart Factor, DO, Professor of Neurology, Director of the Movement Disorders Program and Vance Lanier Chair of Neurology, Emory University School of Medicine
Debra Ehrlich, MD, Chief of the Parkinson’s Disease Clinic, National Institute of Neurological Disorders and Stroke
Speakers will discuss Stem cells, C-ABL therapy, and exercise in the context of Parkinson's Disease therapeutic gaps and developments.
11:30 - 11:45 PM (EST) BREAK
11:45 - 13:20
MAIN PLENARY: PIPELINE PRESENTATIONS - Emerging Neurotherapeutics Pipeline
11:45 AM - 1:15 PM (EST) PIPELINE PRESENTATIONS - Emerging Neurotherapeutics Pipeline
1. NINDS/Division of Translational Research-Funded Drug Discovery and Development Programs
Dr. Mohamed Hachicha, NINDS/Division of Translational Research-Funded Drug Discovery and Development Programs
2. Securing bench to bedside translation with predictive EEG biomarkers of Parkinson's Disease
Dr. Venceslas Duveau, SynapCell
3. EEG Phenotyping as a tool to develop preclinical rodent models of brain disorders for identification and validation of new Neurotherapeutics
Dr. Corinne Roucard, SynapCell
4. An fMRI study for discovering the resting-state functional changes in Schizophrenia using a statistical and ML-based approach
Dr. Indranath Chatterjee, Tongmyong University, Busan, South Korea
5. Toward the use of paramagnetic rim lesions in proof-of-concept clinical trials for treating chronic inflammation in multiple sclerosis
Dr. Jemima Akinsanya, NIH
6. Optimizing Tilorone Analogs as Acetylcholinesterase Inhibitors Using Machine Learning and Recurrent Neural Networks
Dr. Ana Puhl, Collaborations Pharmaceuticals
7. Combined TMS/MRI with deep brain stimulation capability
Dr. Irving Weinberg, Weinberg Medical Physics, Inc.
8. The CURE Epilepsy Catalyst Award: Grant Opportunity For Translational Research in Epilepsy
Dr. Priya Balasubramanian, CURE Epilepsy
1:00 - 1:15 PM (EST) Live Faculty Panel Discussion and Q&A
1:15 - 1:30 PM (EST) BREAK
13:30 - 15:00
POSTER DISCUSSION HALL & Meeting Conclusion Comments from ASENT President
10:00 - 11:45
BREAKOUT SESSION - Brain Organoids as Models of Neurological Disorders and Treatment
10:00 - 10:10 AM (EST) Welcome to ASENT Annual Meeting 2021
Thomas Sutula, MD, PhD, ASENT President | Professor Emeritus, University of Wisconsin-Madison
10:10 - 11:30 AM (EST) BREAKOUT SESSION - Brain Organoids as Models of Neurological Disorders and Treatment
CHAIRS:
C. Anthony Altar, PhD, President and Chief Operating Officer, Splice Therapeutics
Amir Tamiz, PhD, Director of the Division of Translational Research, National Institute of Neurological Disorders and Stroke
Speakers will describe the technology behind creating three-dimensional cell clusters that resemble peripheral and central nervous tissue, and how these CNS and PNS models show phenotypes consistent with CNS tissue, and diseases that plagued donors of the progenitor cells used to make these cell systems. The use of organoids to evaluate known and novel therapeutic agents, including gene therapies, will also be shown.
10:15 - 10:35 AM (EST) Modelling Physiology and Disease with Brain Organoids
Thomas Hartung, MD, Chair for Evidence-based Toxicology with a joint appointment for Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health
10:35 - 10:55 AM (EST) Optimization and Scaling of Patient - Derived Brain Organoids for Disease Phenotyping and Drug Discovery
Gaia Skibinski, PhD, VP of Biology, Herophilus
10:55 - 11:15 AM (EST) 3D Neuronal Spheroids and Organoids for Disease Modeling and Drug Discovery
Emily Lee, PhD, Staff Scientist, National Center for Advancing Translational Sciences (NCATS), NIH
11:15 - 11:30 AM (EST) Live Faculty Panel Discussion and Q&A
Thomas Hartung, MD, Chair for Evidence-based Toxicology with a joint appointment for Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health
Emily Lee, PhD, Staff Scientist, National Center for Advancing Translational Sciences (NCATS), NIH
Gaia Skibinski, PhD, System1 Biosciences
11:30 - 11:45 PM (EST) BREAK
10:00 - 11:45
BREAKOUT SESSION - Parkinson's Disease: New Approaches
10:00 - 10:10 AM (EST) Welcome to ASENT Annual Meeting 2021
Thomas Sutula, MD, PhD, ASENT President | Professor Emeritus, University of Wisconsin-Madison
10:10 - 11:30 AM (EST) BREAKOUT SESSION - Parkinson's Disease: New Approaches
CHAIRS:
Stewart Factor, DO, Professor of Neurology, Director of the Movement Disorders Program and Vance Lanier Chair of Neurology, Emory University School of Medicine
Debra Ehrlich, MD, Chief of the Parkinson’s Disease Clinic, National Institute of Neurological Disorders and Stroke
Speakers will discuss Stem cells, C-ABL therapy, and exercise in the context of Parkinson's Disease therapeutic gaps and developments.
10:15 - 10:35 AM (EST) Stem Cells Therapy in Parkinson's Disease
Edward Wirth, MD, PhD, Chief Medical Officer, Aspen Neuroscience, Inc.
10:35 - 10:55 AM (EST) Disease Modification of Parkinson’s Disease Through Oral Kinase Inhibitor Therapy
Milton Werner, PhD, President and Chief Executive Officer, Inhibikase Therapeutics
10:55 - 11:15 AM (EST) Therapeutically Beneficial Effects of Exercise on Parkinson’s Disease
Daniel Corcos, PhD, Professor, Physical Therapy and Human Movement Sciences, Northwestern University
11:15 - 11:30 AM (EST) Live Faculty Panel Discussion and Q&A
Daniel Corcos, PhD, Professor, Physical Therapy and Human Movement Sciences, Northwestern University
Milton Werner, PhD, President and Chief Executive Officer, Inhibikase Therapeutics
Edward Wirth, MD, PhD, Chief Medical Officer, Aspen Neuroscience, Inc.
11:30 - 11:45 PM (EST) BREAK
13:20 - 14:25
POSTER DISCUSSION & Closing Comments
1:30 - 2:55 PM (EST) POSTER DISCUSSION
MODERATOR:
Carolyn Tallon, PhD, Johns Hopkins University School of Medicine
The following posters presenters will be available for a live Q&A:
28. NINDS/Division of Translational Research-Funded Drug Discovery and Development Programs
Dr. Mohamed Hachicha, NINDS/Division of Translational Research-Funded Drug Discovery and Development Programs
29. Securing bench to bedside translation with predictive EEG biomarkers of Parkinson's Disease
Dr. Venceslas Duveau, SynapCell
30. EEG Phenotyping as a tool to develop preclinical rodent models of brain disorders for identification and validation of new Neurotherapeutics
Dr. Corinne Roucard, SynapCell
31. An fMRI study for discovering the resting-state functional changes in Schizophrenia using a statistical and ML-based approach
Dr. Indranath Chatterjee, Tongmyong University, Busan, South Korea
32. Toward the use of paramagnetic rim lesions in proof-of-concept clinical trials for treating chronic inflammation in multiple sclerosis
Dr. Jemima Akinsanya, NIH
33. Optimizing Tilorone Analogs as Acetylcholinesterase Inhibitors Using Machine Learning and Recurrent Neural Networks
Dr. Ana Puhl, Collaborations Pharmaceuticals
34. Combined TMS/MRI with deep brain stimulation capability
Dr. Irving Weinberg, Weinberg Medical Physics, Inc.
35. The CURE Epilepsy Catalyst Award: Grant Opportunity For Translational Research in Epilepsy
Dr. Priya Balasubramanian, CURE Epilepsy
36. Academic and Industry Physician Workforce Development in Experimental Neurotherapeutics
Dr. Ludy Shih, Boston University School of Medicine
2:55 - 3:00 PM (EST) Meeting Conclusion and Closing Comments from ASENT President
Thomas Sutula, MD, PhD, ASENT President | Professor Emeritus, University of Wisconsin-Madison